Drugs / Ypeginterferon alfa-2b
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT02332473 | Jun 2014 → Feb 2016 | chronic hepatitis B virus infection | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01143662 | Jul 2010 → Apr 2011 | chronic hepatitis B virus infection | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01140997 | Jul 2010 → Jan 2011 | chronic hepatitis C virus infection | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT02327416 | Oct 2014 → Dec 2018 | chronic hepatitis B virus infection | Tongji Hospital | Unknown | Met primary |
| Phase 3 | NCT01760122 | Mar 2013 → Jul 2015 | chronic hepatitis B virus infection | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01581398 | Apr 2012 → Apr 2014 | chronic hepatitis C virus infection | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03332329 | Dec 2015 → Dec 2018 | chronic hepatitis B virus infection | Qin Ning | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ypeginterferon alfa-2b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01581398 ↗ |
| Known as | Peginterferon alfa-2b | “Peginterferon alfa-2b (40KD, Y shape, the followings will refer as Ypeginterferon alfa-2b for short)” NCT01581398 ↗ |
| Modality | Protein / enzyme biologic | “24 weeks of interferon therapy” NCT01581398 ↗ |
| Route | Subcutaneous | “sc, qw, 24 weeks.” NCT01581398 ↗ |